Pfizer
PF-07220060 + PF-07104091 combination dose escalation
Breast Cancer
Countdown
48days
Phase 2 readout · Aug 23, 2026
What's at stake
Phase 2 trial results for PF-07220060 + PF-07104091 combination dose escalation in Breast Cancer are due Aug 23, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT05262400: Phase 2 trial, sponsor Pfizer, drug PF-07220060 + PF-07104091 combination dose escalation. Primary completion date 2026-08-23 (estimated).”